Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.

Clinical experience with insulin glargine in type 1 diabetes. Diabetes Technol Ther (2010) 0.89

Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Ther (2016) 0.77

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77

Insulin analogues. N Engl J Med (2005) 12.24

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care (2005) 8.80

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care (2005) 5.99

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia (2007) 4.41

A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care (2006) 3.91

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes (2004) 3.66

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care (2005) 2.30

Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet (1999) 2.14

The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res (2004) 1.96

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab (2007) 1.80

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med (2007) 1.72

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med (2008) 1.62

Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med (2006) 1.33

Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care (2004) 1.09

Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care (2008) 1.06

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract (2004) 1.00

Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev (2008) 0.94

Weight gain and insulin treatment. Diabetes Metab (2005) 0.93

Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes (2008) 0.92

Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract (2006) 0.90

Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2). Endocr J (2007) 0.89

Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin (2008) 0.86

Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag (2006) 0.81

Insulin glargine in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag (2006) 0.79

[Physicians' experience with increased use of individual reimbursement for pharmaceuticals]. Tidsskr Nor Laegeforen (2008) 0.77

Diabetic foot ulcer burden may be modified by high-dose atorvastatin: A 6-month randomized controlled pilot trial. J Diabetes (2009) 0.90

Dual-energy X-ray absorptiometry is a valid method to estimate visceral adipose tissue in adult patients with Prader-Willi syndrome during treatment with growth hormone. J Clin Endocrinol Metab (2014) 0.79

[Think holistically, think cooperation]. Tidsskr Nor Laegeforen (2013) 0.75

[New steroid card for adrenal insufficiency]. Tidsskr Nor Laegeforen (2012) 0.75

[Not Available]. Tidsskr Nor Laegeforen (2016) 0.75

[Glitazone treatment of type 2 diabetes mellitus]. Tidsskr Nor Laegeforen (2006) 0.75

Tidsskr Nor Laegeforen (2017) 0.75

Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial. Eur J Endocrinol (2005) 0.75